U.S. markets open in 5 hours 21 minutes

Champignon Brands Inc. (SHRMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2971+0.0261 (+9.62%)
At close: 3:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2710
Open0.3050
BidN/A x N/A
AskN/A x N/A
Day's Range0.2800 - 0.3168
52 Week Range0.2210 - 1.7400
Volume251,667
Avg. Volume348,779
Market Cap58.608M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Champignon Provides Update on Disclosure Review

    VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review.  Since the review was commenced, the Company has arranged for: * Filing of business acquisition reports (collectively, the “Business Acquisition Reports”) in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.   * Revocation of the initial cease trade order issued by the Commission on June 19, 2020.   * Preparation of financial disclosure in connection with the acquisition of AltMed Capital Corp. (“AltMed”).  Compilation of the statements is at an advanced stage, and the Company expects this work to be concluded shortly.Continuous Disclosure ReviewOn June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review.  Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws.  In the case of the Company, this review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.  As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review.  As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020.  Concurrently with the revocation, the Commission issued a replacement cease trade order (the “Replacement Order”), pending the filing of a revised material change report (the “Material Change Report”) in connection with the acquisition by the Company of AltMed.The Company previously filed a Material Change Report on May 11, 2020, in connection with the acquisition of AltMed.  The Replacement Order will remain in effect until a revised Material Change Report is filed which contains the disclosure required for a restructuring transaction in accordance with National Instrument 51-102 – Continuous Disclosure Obligations.Prior to finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed.  The Company has concluded, in discussions with its external auditor and accounting advisors, that the acquisition of AltMed should be treated as a reverse-takeover in accordance with IFRS 3 – Business Combinations.  As a result of this conclusion, AltMed is treated as the acquiror for accounting purposes and the Company is in the process of compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.  Compilation of the statements is at an advanced stage, and the Company expects this work to be concluded shortly.The Company remains committed to working with the Commission to assist in completion of the review and revocation of the Replacement Order in a timely fashion.  Compliance with its continuous disclosure obligations remains of paramount importance to the Company, and its board of directors, and the Company will continue to update shareholders as work with the Commission progresses.ON BEHALF OF THE BOARD OF DIRECTORSDr. Roger McIntyre Chief Executive Officer E: info@champignonbrands.comFOR INVESTOR INQUIRIES:Champignon Brands | Storyboard Communications Investor Relations, Toronto, Canada Investor Line:  +1 (833) 375-9995 x611 E: champignonbrands@storyboardcommunications.comFOR CHAMPIGNON BRANDS FRENCH INQUIRIES:Remy Scalabrini Maricom Inc. E: rs@maricom.ca T: (888) 585-MARIThe Canadian Securities Exchange and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary Statement This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company’s ability to finalize financial disclosure surrounding the acquisition of AltMed and meet the requirements prescribed for the revocation of the Replacement Order. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.  There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.

  • GlobeNewswire

    Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence

    VANCOUVER, British Columbia, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”).  Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”). In May 2020, Health Canada approved esketamine for the treatment of MDD. Champignon’s clinic, the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) is Canada's first multidisciplinary community clinic offering rapid-onset treatments for depression and is expected to be the first of its kind to provide this novel treatment for depression in Canada. The CRTCE is located in Mississauga, Ontario.Depression is a leading cause of reduced income in Canada due to workplace disability: adults with MDD lose almost one month of work per year.1 Furthermore, depression, when co-occurring with heart disease, diabetes and other major chronic conditions, can worsen the course of these conditions and raise the risk for premature death.2“The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression to receive an effective, well-tolerated treatment. Moreover, this novel treatment works relatively faster than most conventional treatments for depression,” commented Dr. Roger McIntyre, Champignon’s Chief Executive Officer. “Esketamine has also been observed to help people with MDD when conventional treatments have been insufficient. This provides hope for people affected by MDD to have their symptoms improved and begin to function better again in their lives.”Continuous Disclosure ReviewAs a further update, the Company continues to work with the British Columbia Securities Commission (“BCSC”) to complete its continuous disclosure review. The review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020, and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. The Company continues to fully cooperate with the BCSC to assist in completion of the review in a timely fashion.In connection with the review, on August 26, 2020, the BCSC revoked the cease trade order previously issued against the Company on June 19, 2020, following the filing of business acquisition reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.  Concurrently with the revocation, the BCSC issued a replacement order which will remain in effect pending the filing of an amended material change report in connection with the acquisition of AltMed Capital Corp.Interim Financial StatementsThe Company also announces it will rely on the blanket relief granted by the Alberta Securities Commission Blanket Order 51-517, Temporary Exemption from Certain Corporate Finance Requirements (“BO 51-517”), BC Instrument 51-515, Temporary Exemption from Certain Corporate Finance Requirements (“BCI 51-515”), and Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements (“OI 51-502”), in respect of the filing of its interim financial statements for the period ending June 30, 2020, including the accompanying management’s discussion and analysis and related CEO and CFO certifications (collectively, the “Required Filings”).The Company is working to complete the Required Filings, and addressed comments raised by the BCSC in the course of their disclosure review, within the time period of the extension.  In the interim, all shareholders, including members of the Company’s management and other insiders are subject to a cease trade order issued by the BCSC.  The Company confirms that since the filing of its interim consolidated financial statements for the period ended March 31, 2020, there have been no material developments other than those disclosed through news releases or through disclosure filings completed by the Company on SEDAR (www.sedar.com).1 The effect of bipolar I disorder and major depressive disorder on workforce function McIntyre, R S, MD, FRCPC;Wilkins, K, MSc;Gilmour, H, MA;Soczynska, J K, HBSc;Konarksi, J Z, MSc;M... Chronic Diseases in Canada; 2008; 28, 3 2Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States. Armbrecht E., Shah A., Schepman P., Shah R., Pappadopulos E., Chambers R., Stephens J., Haider S., McIntyre R. S. J Med Econ. 2020;1-11ON BEHALF OF THE BOARD OF DIRECTORSDr. Roger McIntyre Chief Executive Officer E: info@champignonbrands.comFOR INVESTOR INQUIRIES:Champignon Brands | Storyboard Communications Investor Relations, Toronto, Canada Investor Line:  +1 (833) 375-9995 x611 E: champignonbrands@storyboardcommunications.comFOR CHAMPIGNON BRANDS FRENCH INQUIRIES:Remy Scalabrini Maricom Inc. E: rs@maricom.ca T: (888) 585-MARIThe CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary Statement This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements we make regarding the speed and effectiveness of our treatments are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company's limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws;  failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.  There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.

  • GlobeNewswire

    Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

    VANCOUVER, British Columbia, July 24, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of the reports are available for review under the Company’s profile on SEDAR (www.sedar.com). The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review in a timely fashion. The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding recent acquisitions completed by the Company.Champignon also announces it has appointed Dr. Roger McIntyre, Champignon CEO, to its Board of Directors. Dr. McIntyre’s appointment will replace Pat McCutcheon’s position as a director of the Company. Mr. McCutcheon will remain with the Company in an advisory capacity, which will permit him increased mobility to assist the Company with ongoing and planned capital markets initiatives.ON BEHALF OF THE BOARD OF DIRECTORSDr. Roger McIntyre Chief Executive Officer E: info@champignonbrands.comFOR INVESTOR INQUIRIES:Champignon Brands | Storyboard Communications Investor Relations, Toronto, Canada Investor Line: +1 (833) 375-9995 x611 E: champignonbrands@storyboardcommunications.comFOR CHAMPIGNON BRANDS FRENCH INQUIRIES:Remy Scalabrini Maricom Inc. E: rs@maricom.ca T: +1 (888) 585-MARIThe CSE and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary Statement This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements we make regarding the speed and effectiveness of our treatments are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company's limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.